×
S&P 500   3,891.23 (+1.20%)
DOW   31,322.55 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.54 (+1.83%)
MSFT   267.82 (+0.60%)
META   171.40 (+0.96%)
GOOGL   2,348.01 (+2.47%)
AMZN   115.99 (+1.45%)
TSLA   726.34 (+4.48%)
NVDA   157.60 (+4.16%)
NIO   22.28 (+6.96%)
BABA   123.30 (+3.51%)
AMD   79.11 (+4.99%)
MU   58.46 (+1.90%)
CGC   2.69 (+1.51%)
T   21.14 (+0.24%)
GE   62.32 (+1.22%)
F   11.55 (+4.43%)
DIS   97.05 (+1.01%)
AMC   13.73 (+9.23%)
PFE   53.07 (+0.61%)
PYPL   74.86 (+2.21%)
NFLX   189.61 (+3.02%)
S&P 500   3,891.23 (+1.20%)
DOW   31,322.55 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.54 (+1.83%)
MSFT   267.82 (+0.60%)
META   171.40 (+0.96%)
GOOGL   2,348.01 (+2.47%)
AMZN   115.99 (+1.45%)
TSLA   726.34 (+4.48%)
NVDA   157.60 (+4.16%)
NIO   22.28 (+6.96%)
BABA   123.30 (+3.51%)
AMD   79.11 (+4.99%)
MU   58.46 (+1.90%)
CGC   2.69 (+1.51%)
T   21.14 (+0.24%)
GE   62.32 (+1.22%)
F   11.55 (+4.43%)
DIS   97.05 (+1.01%)
AMC   13.73 (+9.23%)
PFE   53.07 (+0.61%)
PYPL   74.86 (+2.21%)
NFLX   189.61 (+3.02%)
S&P 500   3,891.23 (+1.20%)
DOW   31,322.55 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.54 (+1.83%)
MSFT   267.82 (+0.60%)
META   171.40 (+0.96%)
GOOGL   2,348.01 (+2.47%)
AMZN   115.99 (+1.45%)
TSLA   726.34 (+4.48%)
NVDA   157.60 (+4.16%)
NIO   22.28 (+6.96%)
BABA   123.30 (+3.51%)
AMD   79.11 (+4.99%)
MU   58.46 (+1.90%)
CGC   2.69 (+1.51%)
T   21.14 (+0.24%)
GE   62.32 (+1.22%)
F   11.55 (+4.43%)
DIS   97.05 (+1.01%)
AMC   13.73 (+9.23%)
PFE   53.07 (+0.61%)
PYPL   74.86 (+2.21%)
NFLX   189.61 (+3.02%)
S&P 500   3,891.23 (+1.20%)
DOW   31,322.55 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.54 (+1.83%)
MSFT   267.82 (+0.60%)
META   171.40 (+0.96%)
GOOGL   2,348.01 (+2.47%)
AMZN   115.99 (+1.45%)
TSLA   726.34 (+4.48%)
NVDA   157.60 (+4.16%)
NIO   22.28 (+6.96%)
BABA   123.30 (+3.51%)
AMD   79.11 (+4.99%)
MU   58.46 (+1.90%)
CGC   2.69 (+1.51%)
T   21.14 (+0.24%)
GE   62.32 (+1.22%)
F   11.55 (+4.43%)
DIS   97.05 (+1.01%)
AMC   13.73 (+9.23%)
PFE   53.07 (+0.61%)
PYPL   74.86 (+2.21%)
NFLX   189.61 (+3.02%)
NASDAQ:AMED

Amedisys Stock Forecast, Price & News

$116.32
+2.72 (+2.39%)
(As of 07/7/2022 12:04 PM ET)
Add
Compare
Today's Range
$113.65
$117.39
50-Day Range
$105.12
$131.89
52-Week Range
$101.61
$276.21
Volume
8,412 shs
Average Volume
533,645 shs
Market Capitalization
$3.79 billion
P/E Ratio
20.02
Dividend Yield
N/A
Price Target
$170.44

Amedisys MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
47.4% Upside
$170.44 Price Target
Short Interest
Healthy
4.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.40mentions of Amedisys in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$64,055 Sold Last Quarter
Proj. Earnings Growth
15.50%
From $5.29 to $6.11 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

3.08 out of 5 stars

Medical Sector

10th out of 1,433 stocks

Home Health Care Services Industry

1st out of 9 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

Amedisys logo

About Amedisys (NASDAQ:AMED) Stock

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

AMED Stock News Headlines

Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Analysts Set Amedisys, Inc. (NASDAQ:AMED) PT at $173.27
Amedisys (NASDAQ:AMED) PT Lowered to $125.00
Amedisys (NASDAQ:AMED) Price Target Cut to $175.00
See More Headlines

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
21,000
Year Founded
1982

Company Calendar

Last Earnings
4/27/2022
Today
7/07/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$170.44
High Stock Price Forecast
$213.00
Low Stock Price Forecast
$102.00
Forecasted Upside/Downside
+46.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.5625
Research Coverage
16 Analysts

Profitability

Net Income
$209.07 million
Pretax Margin
11.51%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$8.30 per share
Book Value
$29.95 per share

Miscellaneous

Free Float
31,889,000
Market Cap
$3.79 billion
Optionable
Optionable
Beta
0.90

Social Links















Amedisys Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 1 sell rating, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys
or view top-rated stocks.

What is Amedisys' stock price forecast for 2022?

16 brokers have issued 1-year price objectives for Amedisys' shares. Their AMED stock forecasts range from $102.00 to $213.00. On average, they predict Amedisys' share price to reach $170.44 in the next twelve months. This suggests a possible upside of 45.3% from the stock's current price.
View analysts' price targets for Amedisys
or view top-rated stocks among Wall Street analysts.

How has Amedisys' stock performed in 2022?

Amedisys' stock was trading at $161.88 at the beginning of the year. Since then, AMED stock has decreased by 27.5% and is now trading at $117.29.
View the best growth stocks for 2022 here
.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Amedisys
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings data on Wednesday, April, 27th. The health services provider reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.12. The health services provider had revenue of $545.26 million for the quarter, compared to analysts' expectations of $557.81 million. Amedisys had a trailing twelve-month return on equity of 19.37% and a net margin of 8.59%. During the same quarter in the prior year, the business earned $1.54 earnings per share.
View Amedisys' earnings history
.

How will Amedisys' stock buyback program work?

Amedisys announced that its Board of Directors has approved a share repurchase plan on Wednesday, August 4th 2021, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its shares are undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share guidance of $5.23-$5.45 for the period, compared to the consensus EPS estimate of $5.33. The company issued revenue guidance of $2.330-$2.365 billion, compared to the consensus revenue estimate of $2.36 billion.

Who are Amedisys' key executives?

Amedisys' management team includes the following people:

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $117.29.

How much money does Amedisys make?

Amedisys (NASDAQ:AMED) has a market capitalization of $3.82 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $5.81 on an earnings per share basis.

How many employees does Amedisys have?

Amedisys employs 21,000 workers across the globe.

When was Amedisys founded?

Amedisys was founded in 1982.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for Amedisys is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.

This page (NASDAQ:AMED) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.